Charles River Laboratories International vs Incyte
CRL and INCY side by side, both in engineering, accounting, research, management, and related services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRL and INCY compare
Incyte is the larger company, worth 1.4 times as much as Charles River Laboratories International ($24.4B against $17.2B).
Incyte grew revenue faster over the last twelve months (24.9% versus −0.74% for Charles River Laboratories International).
Incyte keeps more of each dollar of sales as profit, with a net margin of 6.7% compared with −6.0% at Charles River Laboratories International.
Incyte scores higher on the StockData Score (13 against 7 for Charles River Laboratories International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRL | INCY |
|---|---|---|
| Size and price | ||
| Market cap | $17.2B | $24.4B |
| Share price | $359.41 | $120.39 |
| Change, 1 year | 99.5% | 33.5% |
| Change, 5 years | −4.2% | 77.4% |
| Beta (5Y) | 1.19 | 0.45 |
| Employees | 20K | 2,844 |
| StockData Score | ||
| Total score | 7 | 13 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 3 (better) |
| Performance score | 2 | 3 (better) |
| Health score | 4 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 64.0× |
| P/S | 4.3× | 4.1× (better) |
| P/B | 6.0× | 4.3× (better) |
| EV/EBITDA | 50.5× | 29.1× (better) |
| P/FCF | 46.3× | – |
| PEG | – | 1.04 |
| FCF yield | 2.2% | – |
| Fair value | $80.65 | $66.29 |
| Margin of safety | −346% | −81.6% (better) |
| Growth | ||
| Revenue growth (TTM) | −0.74% | 24.9% (better) |
| Revenue growth, 5Y average | 6.5% | 14.0% (better) |
| Net income growth (TTM) | – | −66.1% |
| EPS growth (TTM) | – | −68.2% |
| Profitability | ||
| Gross margin | – | 92.7% |
| Operating margin | 2.3% | 10.4% (better) |
| Net margin | −6.0% | 6.7% (better) |
| FCF margin | 9.3% | – |
| Return on equity | −7.7% | 7.8% (better) |
| Return on invested capital | 1.3% | 13.9% (better) |
| Financial health | ||
| Debt / equity | 0.92 (better) | 0.00 |
| Net debt / EBITDA | 6.27 | – |
| Interest coverage | 0.8× | 268× (better) |
| Current ratio | 1.35 | 3.84 (better) |
| Altman Z-score | 3.11 | 10.75 (better) |
| Piotroski F-score | 4 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | 1.9% | – |
| Shareholder yield | 1.9% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 119% | 100.0% |
| Held by insiders | 1.2% | 33.4% |
| Insider net buying, 12 months | −$42.6M (better) | −$58.0M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 6.1% | 7.4% |
Go deeper
- CRL stock overview
- CRL income statement
- CRL valuation and score
- INCY stock overview
- INCY income statement
- INCY valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.